A review of the cost-effectiveness of face-to-face behavioural interventions for smoking, physical activity, diet and alcohol

Chronic Illness

Volumn 3, Issue 2, 2007, Pages 101-129

  Gordon, Louisa ^a,b   Graves, N ^c   Hawkes, A ^b   Eakin, E ^d  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b VIERTEL CENTRE FOR RESEARCH IN CANCER CONTROL   (Australia)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Alcohol intake; Cost effectiveness; Diet; Physical activity; Smoking cessation

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALCOHOL; AMFEBUTAMONE; CALCIUM CHANNEL BLOCKING AGENT; COLESTIPOL; COLESTYRAMINE; NATEGLINIDE; NICOTINE PATCH; PIOGLITAZONE;

ALCOHOL CONSUMPTION; BEHAVIOR MODIFICATION; CHRONIC DISEASE; COST EFFECTIVENESS ANALYSIS; DIET; DOCTOR PATIENT RELATION; DRUG COST; HEALTH CARE; HEALTH CARE COST; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; QUALITY OF LIFE; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SELF HELP; SMOKING; SMOKING CESSATION; SMOKING HABIT; TOBACCO DEPENDENCE;

ALCOHOLISM; BEHAVIOR THERAPY; COST-BENEFIT ANALYSIS; DIET; HEALTH CARE COSTS; HEALTH PROMOTION; HUMANS; MOTOR ACTIVITY; SMOKING CESSATION;

EID: 35348955349     PISSN: 17423953     EISSN: 17459206     Source Type: Journal    
DOI: 10.1177/1742395307081732     Document Type: Review

References (105)

1. Australian Institute of Health and Welfare (AIHW). Australia's health 2004. AIHW cat. no. AUS 44. Canberra: Australian Institute of Health and Welfare, 2004.
2. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA 2004; 291: 1238-45.
3. World Health Organization. World Health Report 2004. Available at: http://www.who.int/whr/2004 (accessed June 2006).
4. World Health Organization. World Health Statistics 2006, Risk factors. Available at: http://www.who.int/whr/2004 (accessed June 2006).
5. Brunner EJ, Thorogood M, Rees K, Hewitt G. Dietary advice for reducing cardiovascular risk. Cochrane Database Syst Rev 2005; CD002128. pub2.(4).
6. Foxcroft DR, Ireland D, Lowe G, Breen R. Primary prevention for alcohol misuse in young people. Cochrane Database Syst Rev 2004; 2002; CD003024.(3).
7. Hillsdon M, Foster C, Thorogood M. Interventions for promoting physical activity. Cochrane Database Syst Rev 2005; CD003180.pub2.(4).
8. Jolliffe JA, Rees K, Taylor RS, Thompson D, Oldridge N, Ebrahim S. Exercise-based rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2001; CD001800.(4).
9. Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev 2005; CD001292.pub2.(2).
10. Lancaster T, Stead LF. Physician advice for smoking cessation. Cochrane Database Syst Rev 2004; CD000165.pub2.(4).
11. Glasgow RE, McKay HG, Piette JD, Reynolds KD. The RE-AIM framework for evaluating interventions: what can it tell us about approaches to chronic illness management?. Patient Educ Couns 2001; 44: 119-27.
12. Ronckers ET, Groot W, Ament AJ. Systematic review of economic evaluations of smoking cessation: standardizing the cost-effectiveness. Med Decis Making 2005; 25: 437-48.
13. Warner KE. Cost effectiveness of smoking-cessation merapies. Interpretation of the evidence-and implications for coverage. Pharmacoeconomics 1997; 11: 538-49.
14. Woolacott NF, Jones L, Forbes CA, et al. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technol Assess Rep 2002; 6: 1-245.
15. Vijgen SM, Hoogendoorn M, Baan CA, de Wit GA, Limburg W, Feenstra TL. Cost effectiveness of preventive interventions in type 2 diabetes mellitus: a systematic literature review. Pharmacoeconomics 2006; 24: 425-41.
16. Brown AI, Garber AM. A concise review of the cost-effectiveness of coronary heart disease prevention. Med Clin North Am 2000; 84: 279-97, ; xi.
17. Brunner E, Cohen D, Toon L. Cost effectiveness of cardiovascular disease prevention strategies: a perspective on EU food based dietary guidelines. Public Health Nutr 2001; 4: 711-15.
18. Krumholz HM, Weintraub WS, Bradford WD, Heidenreich PA, Mark DB, Paltiel AD. Task force #2 - the cost of prevention: can we afford it? Can we afford not to do it? 33rd Bethesda Conference. J Am Coll Cardiol 2002; 40: 603-15.
19. Brown AD, Garber AM. Cost effectiveness of coronary heat disease prevention strategies in adults. Pharmacoeconomics 1998; 14: 27-48.
20. Drummond MF, Stoddard GL, Torrance GW. Methods for the economic evaluation of health care programmes, 1st edn. Oxford: Oxford University Press, 1987.
21. Drummond MF, McGuire A, eds. Economic evaluation in health care, 1st edn. Oxford: Oxford University Press, 2001.
22. Drummond MF, Sculpher M, Torrance GW, O'Brien BJ, Stoddard GL. Methods for the economic evaluation of health care programmes, 3rd edn. Oxford: Oxford University Press, 2005.
23. Honeycutt AA, Clayton L, Khavjou O, et al. Guide to analyzing the cost-effectiveness of community public health prevention approaches. North Carolina: Office of the Assistant Secretary for Planning and Evaluation. Available at: http://aspe.hhs.gov/health/reports/06/cphpa.index.htm (accessed March 2006).
24. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003; 163: 1637-41.
25. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996; 313: 275-83.
26. Organization for Economic Cooperation and Development. OECD Main Economic Indicators. Available at: http://www.oecd.org/findDocument/0,2350, en_2649_34357_1_119656_1_1_1,00.html (accessed April 2006).
27. Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 2003; 26: 2518-23.
28. Fleming MF, Mundt MP, French MT, Manwell LB, Stauffacher EA, Barry KL. Benefit-cost analysis of brief physician advice with problem drinkers in primary care settings. Med Care 2000; 38: 7-18.
29. Brandon TH, Meade CD, Herzog TA, Chirikos TN, Monica S, Cantor AB. Efficacy and cost effectiveness of a minimal intervention to prevent smoking relapse: dismantling the effects of amount of content versus contact. J Consult Clin Psychol 2004; 72: 797-808.
30. Elley R, Kerse N, Arroll B, Swinburn B, Ashton T, Robinson E. Cost-effectiveness of physical activity counselling in general practice. NZ Med J 2004; 117 U: 1216.
31. Pollack HA. Sudden infant death syndrome, maternal smoking during pregnancy, and the cost-effectiveness of smoking cessation intervention. Am J Public Health 2001; 91: 432-6.
32. Chirikos TN, Herzog TA, Meade CD, Webb MS, Brandon TH. Cost-effectiveness analysis of a complementary health intervention: the case of smoking relapse prevention. Int J Technol Assess Health Care 2004; 20: 475-80.
33. Cromwell J, Bartosch WJ, Fiore MC, Baker T, Hasselblad V. Cost effectiveness of the AHCPR guidelines for smoking. JAMA 1997; 278: 1759-66.
34. Feenstra TL, Hamberg-van Reenen HH, Hoogenveen RT, Rutten-van Molken MP. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study. Value Health 2005; 8: 178-90.
35. Fiscella K, Franks P. Cost effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. JAMA 1996; 275: 1247-51.
36. Gilbert AR, Pinget C, Bovet P, Cornuz J, Shamlaye C, Paccaud F. The cost effectiveness of pharmacological smoking cessation therapies in developing countries: a case study in the Seychelles. Tob Control 2004; 13: 190-5.
37. Javitz HS, Swan GE, Zbikowski SM, et al. Cost-effectiveness of different combinations of bupropion SR dose and behavioral treatment for smoking cessation: a societal perspective. Am J Manag Care 2004; 10: 217-26.
38. Crealey GE, McElnay JC, Maguire TA, O'Neill C. Costs and effects associated with a community pharmacy-based smoking-cessation programme. Pharmacoeconomics 1998; 14: 323-33.
39. Meenan RT, Stevens VJ, Hornbrook MC, et al. Cost-effectiveness of a hospital-based smoking cessation intervention. Med Care 1998; 36: 670-8.
40. Song F, Raftery J, Aveyard P, Hyde C, Pelham B, Woolacott N. Cost-effectiveness of pharmacological interventions for smoking cessation: a literature review and a decision analytic analysis. Med Decis Making 2002; 22 Suppl 5: S26-37.
41. Stapleton JA, Lowin A, Russell MA. Prescription of transdermal nicotine patches for smoking cessation in general practice: evaluation of cost-effectiveness. Lancet 1999; 354: 210-15.
42. Mudde AN, de Vries H, Strecher VJ. Cost-effectiveness of smoking cessation modalities: comparing apples with oranges? Prev Med 1996; 25: 708-16.
43. Wasley MA, McNagny SE, Phillips VL, Ahluwalia JS. The cost-effectiveness of the nicotine transdermal patch for smoking cessation. Prev Med 1997; 26: 264-70.
44. Lowin A. Nicotine skin patches: are they cost-effective?. Mental Health Res Rev 1996; 3: 18-20.
45. Spoth RL, Guyll M, Day SX. Universal family-focused interventions in alcohol-use disorder prevention: cost-effectiveness and cost-benefit analyses of two interventions. J Stud Alcohol 2002; 63: 219-28.
46. Fleming MF, Mundt MP, French MT, Manwell LB, Stauffacher EA, Barry KL. Brief physician advice for problem drinkers: long-term efficacy and benefit-cost analysis. Alcohol Clin Exp Res 2002; 26: 36-43.
47. Gentilello LM, Ebel BE, Wickizer TM, Salkever DS, Rivara FP. Alcohol interventions for trauma patients treated in emergency departments and hospitals: a cost benefit analysis. Ann Surg 2005; 241: 541-50.
48. O'Farrell TJ, Choquette KA, Cutter HS, et al. Cost-benefit and cost-effectiveness analyses of behavioral marital therapy as an addition to outpatient alcoholism treatment. J Subst Abuse 1996; 8: 145-66.
49. UKATT. Cost effectiveness of treatment for alcohol problems: findings of the randomised UK alcohol treatment trial (UKATT). BMJ 2005; 331: 544.
50. Briffa TG, Eckermann SD, Griffiths AD, et al. Cost-effectiveness of rehabilitation after an acute coronary event: a randomised controlled trial. Med J Aust 2005; 183: 450-5.
51. Lindholm L. Alcohol advice in primary health care - is it a wise use of resources? Health Policy 1998; 45: 47-56.
52. Corry J, Sanderson K, Issakidis C, Andrews G, Lapsley H. Evidence-based care for alcohol use disorders is affordable. J Stud Alcohol 2004; 65: 521-9.
53. Pettinati HM, Meyers K, Evans BD, et al. Inpatient alcohol treatment in a private healthcare setting: which patients benefit and at what cost? Am J Addict 1999; 8: 220-33.
54. Fals-Stewart W, Klostermann K, Yates BT, O'Farrell TJ, Birchler GR. Brief relationship therapy for alcoholism: a randomized clinical trial examining clinical efficacy and cost-effectiveness. Psychol Addict Behav 2005; 19: 363-71.
55. Weisner C, Mertens J, Parthasarathy S, et al. The outcome and cost of alcohol and drug treatment in an HMO: day hospital versus traditional outpatient regimens. Health Service Res 2000; 35: 791-812.
56. Downs SM, Klein JD. Clinical preventive services efficacy and adolescents' risky behaviors. Arch Pediatr Adolesc Med 1995; 149: 374-9.
57. Ades PA, Pashkow FJ, Nestor JR. Cost-effectiveness of cardiac rehabilitation after myocardial infarction. J Cardiopulm Rehabil 1997; 17: 222-31.
58. Georgiou D, Chen Y, Appado S, et al. Cost-effectiveness analysis of long-term moderate exercise training in chronic heart failure. Am J Cardiol 2001; 87: 984-8; , A984.
59. Lowensteyn I, Coupal L, Zowall H, Grover SA. The cost-effectiveness of exercise training for the primary and secondary prevention of cardiovascular disease. J Cardiopulm Rehabil 2000; 20: 147-55.
60. Dalziel K, Segal L, Elley CR. Cost utility analysis of physical activity counselling in general practice. Aust NZ J Public Health 2006; 30: 57-63.
61. de Vries SO, Visser K, de Vries JA, Wong JB, Donaldson MC, Hunink MG. Intermittent claudication: cost-effectiveness of revascularization versus exercise therapy. Radiology 2002; 222: 25-36.
62. Gordon LG, Scuffham P, Battistutta D, Graves N, Tweeddale M, Newman B. A cost-effectiveness analysis of two rehabilitation support services for women with breast cancer. Breast Cancer Res Treat 2005; 94: 123-33.
63. Munro JF, Nicholl JP, Brazier JE, Davey R, Cochrane T. Cost effectiveness of a community based exercise programme in over 65 year olds: cluster randomised trial. J Epidemiol Community Health 2004; 58: 1004-10.
64. Treesak C, Kasemsup V, Treat-Jacobson D, Nyman JA, Hirsch AT. Cost-effectiveness of exercise training to improve claudication symptoms in patients with peripheral arterial disease. Vasc Med 2004; 9: 279-85.
65. Proper KI, de Bruyne MC, Hildebrandt VH, van der Beek AJ, Meerding WJ, van Mechelen W. Costs, benefits and effectiveness of worksite physical activity counseling from the employer's perspective. Scand J Work Environ Health 2004; 30: 36-46.
66. Sevick MA, Dunn AL, Morrow MS, Marcus BH, Chen GJ, Blair SN. Cost-effectiveness of lifestyle and structured exercise interventions in sedentary adults: results of project ACTIVE. Am J Prev Med 2000; 19: 1-8.
67. Stevens W, Hillsdon M, Thorogood M, McArdle D. Cost-effectiveness of a primary care based physical activity intervention in 45-74 year old men and women: a randomised controlled trial. Br J Sports Med 1998; 32: 236-41.
68. Franz MJ, Splett PL, Monk A, et al. Cost-effectiveness of medical nutrition therapy provided by dietitians for persons with non-insulin-dependent diabetes mellitus. J Am Diet Assoc 1995; 95: 1018-24.
69. Yokoyama KK, Cryar AK, Griffin KC, Godley PJ, Woodward BW. Cost-effectiveness of a multidisciplinary diabetes care clinic. Drug Benefit Trends 2002; 14 Suppl D: 36-44.
70. Olsen J, Willaing I, Ladelund S, Jorgensen T, Gundgaard J, Sorensen J. Cost-effectiveness of nutritional counseling for obese patients and patients at risk of ischemic heart disease. Int J Technol Assess Health Care 2005; 21: 194-202.
71. Brannon SD, Tershakovec AM, Shannon BM. The cost-effectiveness of alternative methods of nutrition education for hypercholesterolemic children. Am J Public Health 1997; 87: 1967-70.
72. Pritchard DA, Hyndman J, Taba F. Nutritional counselling in general practice: a cost effective analysis. J Epidemiol Community Health 1999; 53: 311-16.
73. Tsai AG, Glick HA, Shera D, Stern L, Samaha FF. Cost-effectiveness of a low-carbohydrate diet and a standard diet in severe obesity. Obes Res 2005; 13: 1834-40.
74. Glasgow RE, La Chance PA, Toobert DJ, Brown J, Hampson SE, Riddle MC. Long-term effects and costs of brief behavioural dietary intervention for patients with diabetes delivered from the medical office. Patient Educ Couns 1997; 32: 175-84.
75. Field K, Thorogood M, Silagy C, Normand C, O'Neill C, Muir J. Strategies for reducing coronary risk factors in primary care: which is most cost effective? BMJ 1995; 310: 1109-12.
76. Lindgren P, Fahlstadius P, Hellenius ML, Jonsson B, de Faire U. Cost-effectiveness of primary prevention of coronary heart disease through risk factor intervention in 60-year-old men from the county of Stockholm - a stochastic model of exercise and dietary advice. Prev Med 2003; 36: 403-9.
77. Salkeld G, Phongsavan P, Oldenburg B, et al. The cost-effectiveness of a cardiovascular risk reduction program in general practice. Health Policy 1997; 41: 105-19.
78. Segal L, Dalton AC, Richardson J. Cost-effectiveness of the primary prevention of non-insulin dependent diabetes mellitus. Health Promot Int 1998; 13: 197-209.
79. Wang LY, Yang Q, Lowry R, Wechsler H. Economic analysis of a school-based obesity prevention program. Obes Res 2003; 11: 1313-24.
80. Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 2005; 143: 251-64.
81. Herman WH, Hoerger TJ, Brandle M, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005; 142: 323-32.
82. Malone DC, Raebel MA, Porter JA, et al. Cost-effectiveness of sibutramine in the LOSE Weight Study: evaluating the role of pharmacologic weight-loss therapy within a weight management program. J Manag Care Pharm 2005; 11: 458-68.
83. Raftery JP, Yao GL, Murchie P, Campbell NC, Ritchie LD. Cost effectiveness of nurse led secondary prevention clinics for coronary heart disease in primary care: follow up of a randomised controlled trial. BMJ 2005; 330: 707.
84. Johannesson M, Borgquist L, Jonsson B, Lindholm LH. The cost effectiveness of lipid lowering in Swedish primary health care. The CELL Study Group. J Intern Med 1996; 240: 23-9.
85. Warren E, Brennan A, Akehurst R. Cost-effectiveness of sibutramine in the treatment of obesity. Med Decis Making 2004; 24: 9-19.
86. Finkelstein EA, Troped PJ, Will JC, Palombo R. Cost-effectiveness of a cardiovascular disease risk reduction program aimed at financially vulnerable women: the Massachusetts WISEWOMAN project. J Womens Health Gend Based Med 2002; 11: 519-26.
87. Wylie-Rosett J, Swencionis C, Ginsberg M, et al. Computerized weight loss intervention optimizes staff time: the clinical and cost results of a controlled clinical trial conducted in a managed care setting. J Am Diet Assoc 2001; 101: 1155-62; quiz 1163-1154.
88. Yosefy C, Dicker D, Viskoper JR, Tulchinsky TH, Ginsberg GM, Leibovitz E. The Ashkelon Hypertension Detection and Control Program (AHDC Program): a community approach to reducing cardiovascular mortality. Prev Med 2003; 37: 571-6.
89. Yu CM, Lau CP, Chau J, et al. A short course of cardiac rehabilitation program is highly cost effective in improving long-term quality of life in patients with recent myocardial infarction or percutaneous coronary intervention. Arch Phys Med Rehabil 2004; 85: 1915-22.
90. Fine LJ, Philogene GS, Gramling R, Coups EJ, Sinha S. Prevalence of multiple chronic disease risk factors. 2001 National Health Interview Survey. Am J Prev Med 2004; 27 Suppl 2: 18-24.
91. Goldstein MG, Whitlock EP, DePue J. Multiple behavioral risk factor interventions in primary care. Summary of research evidence. Am J Prev Med 2004; 27 Suppl 2: 61-79.
92. Cornuz J, Gilbert A, Pinget C, et al. Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison. Tob Control 2006; 15: 152-9.
93. Segal L, Mortimer D, Dalziel K. Risk Factor Study. How to reduce the burden from poor nutrition, tobacco smoking, physical inactivity and alcohol misuse: cost-utility analysis of 29 interventions, Melbourne: Centre of Health Economics, Monash University, 2005.
94. Yudkin P, Hey K, Roberts S, Welch S, Murphy M, Walton R. Abstinence from smoking eight years after participation in randomised controlled trial of nicotine patch. Br Med J 2003; 327: 28-9.
95. Tran MT, Holdford DA, Kennedy DT, Small RE. Modeling the cost-effectiveness of a smoking-cessation program in a community pharmacy practice. Pharmacotherapy 2002; 22: 1623-31.
96. Drummond MF, Stoddard GL, Torrance GW. Methods for the economic evaluation of health care programmes, 2nd edn. Oxford: Oxford University Press, 1997.
97. Bala MV, Zarkin GA. Application of cost-effectiveness analysis to multiple products: a practical guide. Am J Manag Care 2002; 8: 211-18.
98. Adler NE, Ostrove JM. Socioeconomic status and health: what we know and what we don't. Ann NY Acad Sci 1999; 896: 3-15.
99. Godfrey C, Parrott S, Coleman T, Pound E. The cost-effectiveness of the English smoking treatment services: evidence from practice. Addiction 2005; 100(Suppl 270-83.
100. Chiou CF, Hay JW, Wallace JF, et al. Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care 2003; 41: 32-44.
101. Stearns SC, Drummond M. Grading systems for cost-effectiveness studies: is the whole greater than the sum of the parts?. Med Care 2003; 41: 1-3.
102. Mortimer D, Segal L, Proper KI, et al. Economic evaluation of interventions for problem drinking and alcohol dependence: cost per QALY estimates. Alcohol Alcohol 2005; 40: 549-55.
103. Johannesson M, Agewall S, Hartford M, Hedner T, Fagerberg B. The cost-effectiveness of a cardiovascular multiple-risk-factor intervention programme in treated hypertensive men. J Intern Med 1995; 237: 19-26.
104. Oldenburg B, Owen N, Parle M, Gomel M. An economic evaluation of four work site based cardiovascular risk factor interventions. Health Educ Q 1995; 22: 9-19.
105. Lindholm L, Rosen M, Weinehall L, Asplund K. Cost effectiveness and equity of a community based cardiovascular disease prevention programme in Norsjo, Sweden. J Epidemiol Community Health 1996; 50: 190-5.